These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 24846822

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
    Richarz U, Waechter S, Sabatowski R, Szczepanski L, Binsfeld H.
    Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
    [Abstract] [Full Text] [Related]

  • 3. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R.
    Pain Pract; 2010 Jan; 10(5):404-15. PubMed ID: 20384968
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M, Tudor IC, Khanna S, Thipphawong J.
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME, Dvergsten C, Gimbel J.
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [Abstract] [Full Text] [Related]

  • 7. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
    Rauck R, Rapoport R, Thipphawong J.
    Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C.
    Pain Physician; 2013 Jan; 16(3):E237-46. PubMed ID: 23703422
    [Abstract] [Full Text] [Related]

  • 10. Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivity.
    Cruciani RA, Katz N, Portenoy RK.
    J Pain; 2012 Apr; 13(4):379-89. PubMed ID: 22424912
    [Abstract] [Full Text] [Related]

  • 11. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
    Hale M, Khan A, Kutch M, Li S.
    Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
    Nicholson B, Ross E, Sasaki J, Weil A.
    Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
    [Abstract] [Full Text] [Related]

  • 14. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
    Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT, Dornseif BE, Damask MC.
    J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J.
    Clin Drug Investig; 2010 May; 30(8):489-505. PubMed ID: 20586515
    [Abstract] [Full Text] [Related]

  • 20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.
    Pain Pract; 2008 May; 8(4):287-313. PubMed ID: 18503626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.